Article
Nomad Bioscience Inks Licensing Pact with Bayer Innovation and Icon Genetics Group
Author(s):
Nomad Bioscience GmbH (Munich, Germany) has entered into a broad licensing agreement with Bayer Innovation GmbH (Düsseldorf, Germany) and Icon Genetics group (Halle, Germany).
Nomad Bioscience GmbH (Munich, Germany) has entered into a broad licensing agreement with Bayer Innovation GmbH (Düsseldorf, Germany) and Icon Genetics group (Halle, Germany).
The agreement provides Nomad access to Icon's proprietary technology platforms, including its transient expression technology, magnICON, for manufacturing biomaterials and selected biosimilar pharmaceutical proteins in green plants. The financial terms of the agreement are not disclosed.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
